Yong Wha Moon

11PUBLICATIONS
17CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 06, 2026
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.

|Apr 24, 2025
SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer.

Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal

|Nov 09, 2024
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.

Sa Deok Hong, Nar Bahadur Katuwal, Min Sil Kang

|Dec 09, 2023
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.

Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal

|Oct 14, 2023
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.

Yeong Gyu Jeong, Nar Bahadur Katuwal, Min Sil Kang

|Jan 11, 2022
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.

Kamal Pandey, Nar Bahadur Katuwal, Nahee Park

Pageof 2

Frequent Collaborators

6 joint publications

Nar Bahadur Katuwal

5 joint publications

Kamal Pandey

3 joint publications

Min Sil Kang

3 joint publications

Nahee Park